OpGen’s Subsidiary Curetis Signs Expansion of R&D Collaboration with FIND
April 05 2023 - 7:30AM
OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a
precision medicine company harnessing the power of molecular
diagnostics and bioinformatics to help combat infectious disease,
reported today that it signed an amendment to its research and
development (“R&D”) collaboration agreement with FIND, to
expand the collaboration which was originally started in fall of
2022.
The work already completed under the
collaboration will be expanded by three work packages increasing
total project volume to up to € 830 thousand in revenue potential.
The added deliverables will address the following topics:
- An Antimicrobial Stewardship Module supporting users with
rule-based information to allow making the best treatment choices
based on respective hospital’s drug availability;
- A “Data everywhere” concept,
investigating hardware and software options for remote connectivity
in the specific environments of low- and middle- income countries
(LMICs); and
- Next Generation Sequencing (“NGS”)
strain analysis including isolates from several sub-Saharan African
countries to investigate any potential sequence differences.
Dr. Gerd Luedke, Director Innovation, Technology
and IP at OpGen’s German subsidiary Curetis GmbH commented: “As we
approach the final milestones from the original first phase of our
collaboration agreement, we are excited to expand the scope of our
R&D partnership with FIND. We believe these additional steps
will help us in the development of a more robust and suitable
solution in LMIC countries down the road, a goal we have for the
possible next phase of this collaboration under a new
agreement.”
Dr. Cecilia Ferreyra, Director, FIND AMR
Programme remarked that, “We look forward to seeing and evaluating
the final milestone data as well as getting data from these
expanded set of milestone deliverables in the coming quarter. It
will help our team to better evaluate the potential of Unyvero A30
to help identify blood stream infections in patients admitted to
LMIC hospitals.”
About OpGen,
Inc.
OpGen, Inc. (Rockville, Md., U.S.A.) is a
precision medicine company harnessing the power of molecular
diagnostics and bioinformatics to help combat infectious disease.
Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH,
we are developing and commercializing molecular microbiology
solutions helping to guide clinicians with more rapid and
actionable information about life threatening infections to improve
patient outcomes, and decrease the spread of infections caused by
multidrug-resistant microorganisms, or MDROs. OpGen’s current
product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the
ARES Technology Platform including ARESdb, NGS technology and
AI-powered bioinformatics solutions for antibiotic response
prediction including ARESiss, ARESid, ARESasp, and AREScloud, as
well as the Curetis CE-IVD-marked PCR-based SARS-CoV-2 test
kit.
For more information, please
visit www.opgen.com.
Forward-Looking Statements
This press release includes statements regarding
OpGen’s collaboration with FIND. These statements and other
statements regarding OpGen’s future plans and goals constitute
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934 and are intended to qualify for the safe
harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Such statements are subject to risks
and uncertainties that are often difficult to predict, are beyond
our control, and which may cause results to differ materially from
expectations. Factors that could cause our results to differ
materially from those described include, but are not limited to,
the success of our commercialization efforts, our ability to
successfully, timely and cost-effectively develop, seek and obtain
regulatory clearance for and commercialize our product and services
offerings, the rate of adoption of our products and services by
hospitals and other healthcare providers, the fact that we may not
effectively use proceeds from recent financings, the continued
impact of COVID-19 on the Company’s operations, financial results,
and commercialization efforts as well as on capital markets and
general economic conditions, our ability to satisfy debt
obligations under our loan with the European Investment Bank, the
effect of the military action in Russia and Ukraine on our
distributors, collaborators and service providers, our liquidity
and working capital requirements, the effect on our business of
existing and new regulatory requirements, our ability to realize
any anticipated benefits from the reverse stock split, including
maintaining its listing on the Nasdaq Capital Market and attracting
new investors, and other economic and competitive factors. For a
discussion of the most significant risks and uncertainties
associated with OpGen's business, please review our filings with
the Securities and Exchange Commission. You are cautioned not to
place undue reliance on these forward-looking statements, which are
based on our expectations as of the date of this press release and
speak only as of the date of this press release. We undertake no
obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
OpGen:Oliver SchachtPresident and
CEOInvestorRelations@opgen.com
OpGen Investor & Press Contact:Alyssa
FactorEdison Groupafactor@edisongroup.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jul 2023 to Jul 2024